home / stock / rnxt / rnxt quote
Last: | $1.15 |
---|---|
Change Percent: | 1.77% |
Open: | $1.2 |
Close: | $1.13 |
High: | $1.2 |
Low: | $1.11 |
Volume: | 14,875 |
Last Trade Date Time: | 06/27/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.15 | $1.2 | $1.13 | $1.2 | $1.11 | 14,875 | 06-27-2024 |
$1.13 | $1.11 | $1.13 | $1.18 | $1.11 | 27,621 | 06-26-2024 |
$1.13 | $1.09 | $1.13 | $1.2139 | $1.0801 | 61,541 | 06-25-2024 |
$1.145 | $1.14 | $1.145 | $1.195 | $1.11 | 28,091 | 06-24-2024 |
$1.1 | $1.299 | $1.1 | $1.3 | $1.1 | 212,557 | 06-21-2024 |
$1.3 | $1.34 | $1.3 | $1.38 | $1.24 | 54,358 | 06-20-2024 |
$1.37 | $1.35 | $1.37 | $1.41 | $1.33 | 175,935 | 06-19-2024 |
$1.37 | $1.35 | $1.37 | $1.41 | $1.33 | 175,935 | 06-18-2024 |
$1.35 | $1.29 | $1.35 | $1.35 | $1.24 | 159,269 | 06-17-2024 |
$1.18 | $1.03 | $1.18 | $1.23 | $1.03 | 88,267 | 06-14-2024 |
$1.05 | $1.15 | $1.05 | $1.16 | $1.0401 | 104,751 | 06-13-2024 |
$1.17 | $1.1 | $1.17 | $1.34 | $1.06 | 202,056 | 06-12-2024 |
$1.05 | $1.05 | $1.05 | $1.14 | $1.03 | 105,792 | 06-11-2024 |
$1.03 | $1.01 | $1.03 | $1.08 | $1 | 75,178 | 06-10-2024 |
$1.02 | $1.03 | $1.02 | $1.06 | $1.015 | 45,944 | 06-07-2024 |
$1.05 | $1.08 | $1.05 | $1.08 | $1.0314 | 74,592 | 06-06-2024 |
$1.07 | $1.1 | $1.07 | $1.15 | $1.05 | 50,457 | 06-05-2024 |
$1.0686 | $1.12 | $1.0686 | $1.13 | $1.02 | 59,050 | 06-04-2024 |
$1.15 | $1.15 | $1.15 | $1.22 | $1.11 | 34,295 | 06-03-2024 |
$1.16 | $1.22 | $1.16 | $1.29 | $1.15 | 13,225 | 05-31-2024 |
News, Short Squeeze, Breakout and More Instantly...
RenovoRx Inc. Company Name:
RNXT Stock Symbol:
NASDAQ Market:
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx is well positioned to advance its pivotal Phase III clinical trial, expand development pipeline into additional cancer indications and explore new commercial business development opportunities with its therapeutic t...